We apply insights and innovation at each stage of our business and utilize our internal capabilities and those of our partners around the world. The table below summarizes the status of our key programs for internal development or co-development.
Chronic Obstructive Pulmonary Disease
Janus kinase inhibitor
Neurogenic Orthostatic Hypotension
Initial clinical safety testing into patients or healthy human volunteers, or studies directed toward understanding the mechanisms of action of the drug
Further clinical safety testing and preliminary efficacy testing in a limited patient population
Evaluation of clinical efficacy and safety within an expanded patient population
A marketing application has been submitted to a regulatory authority